SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
University of Washington
University of Washington
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Emory University
Rutgers, The State University of New Jersey
University of Southern California
University of Kansas Medical Center
University of Pittsburgh
Abramson Cancer Center at Penn Medicine
Intergroupe Francophone de Cancerologie Thoracique
Oncology Institute of Southern Switzerland
Intergroupe Francophone de Cancerologie Thoracique
University of California, Irvine
SCRI Development Innovations, LLC
The Methodist Hospital Research Institute
Centre Francois Baclesse
University College, London
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Fundación GECP
Fundación GECP
Vanderbilt-Ingram Cancer Center
Spanish Lung Cancer Group
Hunan Province Tumor Hospital
Swiss Cancer Institute
Hunan Province Tumor Hospital
University Hospital Heidelberg
University of Kansas Medical Center
Gruppo Oncologico Italiano di Ricerca Clinica
University Hospital, Ghent
Duke University
Columbia University
Centre Georges Francois Leclerc
Fondazione per la Medicina Personalizzata
Gustave Roussy, Cancer Campus, Grand Paris
University of Milano Bicocca
University of Washington
Fred Hutchinson Cancer Center
Alliance Foundation Trials, LLC.
Samsung Medical Center
Jules Bordet Institute
Big Ten Cancer Research Consortium
Chonnam National University Hospital
Mayo Clinic
University of California, Davis
Fundación GECP
University Hospital, Brest
Washington University School of Medicine
Yonsei University
European Lung Cancer Working Party
Oslo University Hospital